^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    ALK translocation

    i
    Other names: NBLST3, CD246, Anaplastic Lymphoma Kinase, Anaplastic Lymphoma Kinase (Ki-1), CD246 Antigen, Mutant Anaplastic Lymphoma Kinase, ALK, ALK Receptor Tyrosine Kinase, Anaplastic Lymphoma Receptor Tyrosine Kinase, ALK Tyrosine Kinase Receptor
    Entrez ID:
    238
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    Related tests:
    7d
    KEYNOTE-603: Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors (clinicaltrials.gov)
    P1, N=242, Active, not recruiting, ModernaTX, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • TMB (Tumor Mutational Burden)
    |
    EGFR mutation • ALK positive • ALK translocation • EGFR positive
    |
    Keytruda (pembrolizumab) • MK-3475 SC • intismeran autogene (mRNA-4157)
    9d
    NIRVANA-LUNG: PD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=327, Recruiting, UNICANCER | Active, not recruiting --> Recruiting | Trial completion date: Jul 2027 --> Dec 2026 | Trial primary completion date: Jan 2026 --> Dec 2026
    Enrollment open • Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    EGFR mutation • ALK positive • ALK translocation
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • albumin-bound paclitaxel • pemetrexed
    11d
    LIST: A Study of Participants With Advanced Non-Small Cell Lung Cancer Treated With Nivolumab in France After at Least One Prior Chemotherapy-based Treatment by Lung Initiative on Sequence Therapy (clinicaltrials.gov)
    P=N/A, N=535, Completed, Bristol-Myers Squibb | Active, not recruiting --> Completed | Trial completion date: Sep 2025 --> Apr 2025 | Trial primary completion date: Sep 2025 --> Apr 2025
    Trial completion • Trial completion date • Trial primary completion date • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    BRAF mutation • ALK translocation
    |
    Opdivo (nivolumab)
    18d
    Beyond ALK fusion positivity: structural complexity as a prognostic indicator in first-line ALK-TKI therapy. (PubMed, Clin Transl Oncol)
    Nonreciprocal/reciprocal ALK translocations represent an independent adverse prognostic factor for ALK-positive NSCLC patients compared with solitary 3'-ALK fusions. However, their poorer prognosis does not appear to be directly associated with TP53 co-mutations.
    Journal
    |
    ALK (Anaplastic lymphoma kinase) • TP53 (Tumor protein P53) • EML4 (EMAP Like 4)
    |
    TP53 mutation • ALK positive • ALK rearrangement • ALK fusion • ALK translocation
    24d
    First description of ALK-positive NSCLC in a heart transplant patient (PubMed, Pneumologie)
    ALK translocation is a rare driver mutation in non-small cell lung cancer. This is a case report about treatment of a heart transplanted patient with ALK-positive non-small cell lung cancer.
    Journal
    |
    ALK (Anaplastic lymphoma kinase)
    |
    ALK positive • ALK translocation
    1m
    GARNET: Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=738, Active, not recruiting, Tesaro, Inc. | Recruiting --> Active, not recruiting | Trial completion date: Oct 2027 --> Jan 2027
    Enrollment closed • Trial completion date
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • MSI (Microsatellite instability) • MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2)
    |
    EGFR mutation • MSI-H/dMMR • ALK translocation
    |
    Jemperli (dostarlimab-gxly)
    1m
    MicroRNAs and lung cancer: overview of essential pathways and somatic mutations in cancer progression. (PubMed, Front Oncol)
    Specifically, we highlight the modulatory roles of miRNA in cancer cell survival and proliferation (miR-28, miR-30b/c), invasion and metastasis (miR-218, miR-182), neoangiogenesis (miR-29c), metabolic reprogramming (miR-124), and therapy resistance (miR-378, miR-328, miR-1244). The broad implications of miRNAs in lung cancer underline their potential real-world utility, as these entities can function as biomarkers for prognosis/diagnosis and even future therapeutic targets or agents.
    Review • Journal
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • MIR200C (MicroRNA 200c) • MIR30B (MicroRNA 30b) • NTRK (Neurotrophic receptor tyrosine kinase) • MIR182 (MicroRNA 182) • MIR328 (MicroRNA 328) • MIR218 (MicroRNA 218) • MIR22 (MicroRNA 22) • MIR33A (MicroRNA 33a)
    |
    KRAS mutation • EGFR mutation • KRAS G12C • BRAF mutation • ALK rearrangement • ROS1 fusion • ROS1 rearrangement • RET rearrangement • KRAS G12 • ALK translocation • NTRK fusion
    2ms
    QUILT2023: Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=1538, Active, not recruiting, ImmunityBio, Inc. | Trial completion date: Apr 2026 --> Dec 2026 | Trial primary completion date: Oct 2025 --> Oct 2026
    Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    PD-L1 expression • EGFR mutation • BRAF mutation • ALK translocation
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • cisplatin • Tecentriq (atezolizumab) • Yervoy (ipilimumab) • carboplatin • albumin-bound paclitaxel • pemetrexed • Anktiva (nogapendekin alfa inbakicept-pmln)
    2ms
    Early years, advanced disease: The unmet need in young adults with non-small cell lung cancer. (PubMed, Eur J Cancer)
    Early-onset LC is characterized by advanced disease stage, adenocarcinoma histopathology and frequent targetable genomic alterations, especially in patients without a history of smoking. Early diagnosis remains a critical unmet medical need in this subgroup of patients.
    Journal
    |
    ALK (Anaplastic lymphoma kinase)
    |
    ALK translocation
    3ms
    Rebiopsy Feasibility and Clinical Impact on Metastatic Non-Small-Cell Lung Cancer With EGFR/ALK/ROS Oncogenic Driver Progression After Optimal Targeted Therapy: A Multicenter Real-World Analysis. (PubMed, Clin Lung Cancer)
    In this population of patients with oncogenic driver progression under optimal targeted TKIs and in sufficiently good general condition to be included in an immunochemotherapy trial, only half were re-biopsied. Rebiopsy does not seem to improve the outcomes of these patients.
    Journal • Real-world evidence
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    EGFR mutation • ALK translocation
    3ms
    NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922) (clinicaltrials.gov)
    P1, N=65, Completed, New Approaches to Neuroblastoma Therapy Consortium | Active, not recruiting --> Completed | Trial completion date: Dec 2025 --> Jan 2025
    Trial completion • Trial completion date
    |
    ALK fusion • ALK mutation • ALK translocation
    |
    Lorbrena (lorlatinib) • cyclophosphamide • topotecan • Neulasta (pegfilgrastim) • Neupogen (filgrastim)
    3ms
    Unilateral cystic and bullous lung changes in a patient treated with brigatinib: a case report. (PubMed, Korean J Clin Oncol)
    According to European Society for Medical Oncology guidelines patients with ALK translocation and performance status 0-3 can be offered 1st line treatment with TKI (brigatinib, alectinib, or lorlatinib). Here, we describe a 37-year-old male, a never-smoker, who developed progressively diffuse cystic changes in the lung parenchyma while receiving brigatinib treatment for NSCLC with intrapulmonary metastases. Clinicians should remain vigilant for this potential atypical pulmonary adverse effect, including the possibility of cystic or bullous transformations in the lung parenchyma.
    Journal
    |
    ALK (Anaplastic lymphoma kinase)
    |
    ALK rearrangement • ALK translocation
    |
    Alecensa (alectinib) • Lorbrena (lorlatinib) • Alunbrig (brigatinib)